Industry & Policy News

[Bloomberg] Patients describe a distinct before-and-after from gene therapy, but it’s less a lightning bolt than a slow dawning that begins by waking up one morning and realizing that their pain is gone.

[Institute of Cancer Research] The Institute of Cancer Research is one of the founding members of a new not-for-profit company that will enable scientists across the world to test cancer drugs in cell and animal models of childhood cancers.

[Fierce Biotech] A look at interim data on nanrilkefusp alfa, also known as SOT101, has revealed “insufficient efficacy to warrant further development in larger randomized trials” in the settings targeted to date, prompting Sotio to immediately stop enrollment in three studies.

[Ocular Therapeutix, Inc.] Ocular Therapeutix, Inc. announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the company’s axitinib intravitreal implant, for the treatment of wet age-related macular degeneration (wet AMD).

[ContraFect, Corp.] ContraFect, Corp. announced that the US FDA completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, and concluded that the company may proceed with its Phase I clinical study.

[Fierce Biotech] Ichnos Sciences has finally found a buyer for its OX40 eczema program. Astria Therapeutics has taken the other side of the deal, paying $15 million upfront to secure a spot at the back of a race led by Amgen and Sanofi.